Retatrutide is the next-generation triple-agonist peptide that has exploded in popularity across the United States for one reason: fast, sustained weight loss. Where older GLP-1 compounds typically delivered 12–15% bodyweight reduction, published Phase-2 trial data on Retatrutide reported up to 24% bodyweight loss at 48 weeks — the largest result ever recorded for this class of peptide. Until now, getting it in Australia meant ordering from US suppliers, waiting six weeks, and hoping the parcel didn't sit in customs. Retatrutide... read full review »